News
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...
Investor's Business Daily on MSN21h
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.
StockStory.org on MSN5d
The Top 5 Analyst Questions From Moderna’s Q1 Earnings CallModerna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations ...
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback